Tradestie Institutional Equity Comparison Engine

CVM vs OVID โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

OVID Overall Edge

OVID Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ovid Therapeutics Inc. Common Stock (OVID) driven by superior Valuation, Momentum & Technical, Options & Structure while CVM counters with relative strength in Growth & Margin. Fundamentally, CVM trades at 23.0x Forward P/E with 0.0% operating margin (-62.7% YoY revenue) versus OVID at 1.8x Forward P/E and -4693.7% operating margin (-88.3% YoY). In options structure, CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against OVID sits in CONSOLIDATION (34th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner OVID
CVM 23.0x vs OVID 1.8x Fwd P/E
Growth & Margin Winner CVM
Op Margin 0.0% vs -4693.7% ยท YoY -62.7% vs -88.3%
Momentum & Technical Winner OVID
1Y -77.5% vs +114.6% ยท 52W Pos 10% vs 72%
Options & Structure Winner OVID
BREAKDOWN (N/A IV) vs CONSOLIDATION (34th %ile IV)
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
1M Return -11.17%
1Y Return -77.48%
Forward P/E 23.0x
Unified AI Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0
OVID NASDAQ
Ovid Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.58
+1.38% 1D
Market Cap $462.6M
1M Return +19.77%
1Y Return +114.58%
Forward P/E 1.8x
Unified AI Score
44.9 / 100 HOLD
Tech 15.0 Fund 42.0 Flow 67.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CVM -77.48% OVID +114.58% Spread: +173.3 pp (OVID Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CVM Revenue OVID Revenue CVM Op. Margin OVID Op. Margin Margin Edge
FY2013 $0M N/A -12450.1% N/A CVM
FY2014 $0M N/A -9721.4% N/A CVM
FY2020 N/A $10M N/A -645.4% OVID
FY2021 N/A $210M N/A 59.6% OVID
FY2022 N/A $0M N/A -3696.4% OVID
FY2023 N/A $0M N/A -15122.7% OVID
FY2024 N/A $0M N/A -10933.7% OVID
FY2025 N/A $10M N/A -585.2% OVID

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CVM (3) vs OVID (6)
Institutional Metric CVM OVID Criterion Row Winner
Market Capitalization Scale $20.9M $462.6M Larger Scale OVID
Trailing P/E Ratio Valuation 23.0x 1.8x Lower Multiple OVID
Forward P/E Ratio Valuation 23.0x 1.8x Lower Multiple OVID
Revenue Growth (YoY) Growth -62.7% -88.3% Higher Growth CVM
Operating Margin (TTM) Profitability 0.0% -4693.7% Higher Margin CVM
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -252.5% -35.4% Higher ROE OVID
52-Week Range Position Momentum 10% ($1โ€“$8) 72% ($1โ€“$3) Stronger Trend OVID
Beta / 30D Volatility Risk Regime 0.65ฮฒ ยท 120% Vol 0.92ฮฒ ยท 97% Vol Lower Realized Risk OVID
Unified Institutional Score Composite Signal 56.6 / 100 (HOLD) 44.9 / 100 (HOLD) Higher Composite CVM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CVM vs OVID Buy Guide
CVM BREAKDOWN
29d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CVM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
OVID CONSOLIDATION
150d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 34th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live OVID Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CVM nor OVID registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.